Vitamin D supplementation may be able to offset bone loss in people who take canagliflozin (a common diabetes drug). Researchers will present their research at the American Physiological Society, (APS), and American Society for Nephrology. Control of Renal Function in Health and Disease conferenceCharlottesville, Virginia
A class of diabetes drugs called SGLT2 inhibits has been shown slowing the progression of diabetes-related renal disease. It is now being considered as a first-line treatment option by people with diabetes at high risk of developing kidney or heart disease. However, some studies show that SGLT inhibitors can adversely affect bone health by accelerating bone mineral loss and hindering the body’s activation of vitamin. Combining these events can increase your risk of fracture. Researchers from the University of Maryland School of Medicine suggest that people who have lower levels of vitamin A may have a higher chance of bone fractures and bone loss if they are taking SGLT2 inhibiters.
The research team examined adults from Lancaster, Pennsylvania’s Old Order Amish community. Researchers explained that they chose this population because of the extensive genetic sequencing data and also because the farm-fresh milk that Amish residents drink is not fortified in vitamin D. This makes it more likely that Amish people have a lower intake of vitamin D than the general population.
The volunteers—some of whom were found to have preexisting low vitamin D levels—took canagliflozin, an SGLT2 inhibitor, for five days before and after they were given vitamin D supplements. Researchers found that canagliflozin caused a significant drop in vitamin D levels in vitamin D-deficient people (31%), but a smaller drop in normal vitamin D status (7%) Supplements then increased levels of parathyroid hormone (which regulates calcium levels and vitamin D levels in bones),
The research team stated that vitamin D supplements for bone health were effective in countering the negative effects of SGLT2 inhibitors. However, more research is needed. “Longer term follow-up will be required to determine whether this accelerated loss of bone mineral density will eventually translate into an increased risk of bone fracture over the course of 10–20 years of chronic therapy,” said Zhinous Yazdi, MD, first author of the study. “Accordingly we recommend that patients and their physicians consider vitamin D supplements to restore normal vitamin A status in vitamin D-deficient individuals who receive (or will receive) SGLT2 inhibiters.
Are vitamin D supplements able to provide kidney-related benefits to individuals at high risk for diabetes?
Vitamin D supplements could help to offset bone loss due to diabetes drug (2022, June 27, 2012)
Retrieved 28 June 2022
This document is subject copyright. Except for any fair dealings in private study or research, this document is not subject to copyright.
Part may not be reproduced without written permission. This content is only for informational purposes.
Source: medical xpress.